miR-342 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,150 results for “miR-342”

Trials

View all 3617 →

miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction

40 participants · First posted Jan 20, 2026

miR-200b & miR-21 in Diabetic Wounds

98 participants · First posted Oct 20, 2015

PETACC-8 miR-31-3p and miR-31-5p Ancillary Study

1,808 participants · First posted Dec 5, 2017

Drugs

View all 926 →

BOS-342

miR-302

FCN-342

Organizations

View all 99 →

MIR SCIENTIFIC LLC

United States

Regulus Therapeutics

United States

Aviceda Therapeutics, Inc.

United States

News

View all 508 →

Australian researchers uncover molecular switch driving triple-negative breast cancer metastasis, pointing to CDK4/6 inhibitor repurposing

CSF Biomarkers NfL, CHIT1, and miR-181b Evaluated for ALS Diagnosis and Prognosis

HDAC Inhibition in Muscle Cells Enhances Bone Regeneration via Extracellular Vesicles

Page 1 of 515